Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
American Battery Technology Company reported a net loss of $14.6 million for the quarter ended September 30, 2026, compared to a $10.3 million loss in the prior year. While revenue increased to $1.7 million, the company faced a gross loss of $3.6 million and significantly higher operating expenses driven by general, administrative, and R&D costs.
Ensysce Biosciences reported a significant net loss of $88.2 million for the nine months ended September 30, 2026, primarily driven by a $79.9 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity position, ending the period with $29.7 million in cash following multiple preferred stock and PIPE financing transactions.
Magnite Insider James Rossman Sells $1.43M of Stock
James Rossman sold 49,190 shares of Magnite, Inc. at $29.05 a share, worth $1.43M in total on Nov 11, 2026. Shares held after the trade: 58,287 (-45.8%).
Addus HomeCare EVP, Chief Govt Rel Officer Darby Anderson Sells $827K of Stock
Darby Anderson, EVP, Chief Govt Rel Officer, sold 6,740 shares of Addus HomeCare Corp at $122.30 to $123.41 a share (average $122.72) in 2 transactions, worth $827K in total on Nov 10, 2026. Shares held after the trade: 46,246 (-5.2%).
MediciNova reported a net loss of $7.7 million for the nine months ended September 30, 2026, an improvement from the $9.2 million loss in the prior year period. The company strengthened its liquidity by raising $6.2 million through an at-the-market equity offering, ending the quarter with $29.3 million in cash and cash equivalents.
Claritev Insider Ares Management LLC Buys $2.94M of Stock
Ares Management LLC bought 115,579 shares of Claritev Corp at $24.42 to $26.14 a share (average $25.40) in 2 transactions, worth $2.94M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,049,518 (+3.3%).
Aethlon Medical reported financial results for its fiscal second quarter ended September 30, 2026, highlighting a cash position of $6.5 million and a 77.2% increase in operating expenses due to merger-related professional fees. The company is currently progressing through a definitive merger agreement with North Immunology, Inc., which includes a contingent value right (CVR) for existing shareholders related to the legacy Hemopurifier business.
“We advanced our clinical program during the quarter. We treated the second participant in the third and final dosing cohort of our Phase 1 oncology study in Australia. We have treated eight patients across the three dosing cohorts to date and continue to pursue enrollment of one additional patient.”
Hagerty Signs $148M M&A Deal with Hagerty Holding Corp.
Hagerty, Inc. announced the pricing and closing of a secondary offering of 10,000,000 shares of Class A common stock by its majority stockholder, Hagerty Holding Corp., at $14.85 per share. The company did not receive any proceeds from the sale, as the shares were previously issued and the offering was intended to facilitate a secondary sale by the selling stockholder.
New Jersey Resources approved its Fiscal 2027 Officer Annual Incentive Plan and granted long-term incentive awards to its named executive officers. The awards include performance share units tied to total shareholder return and cumulative net financial earnings per share, as well as restricted stock units. The annual incentive plan sets target cash opportunities ranging from 40% to 110% of base salary based on financial and leadership performance criteria.
Prairie Operating Co. reported its Q3 2026 financial results, highlighted by a 31% sequential revenue increase to $129.5 million and a 21% increase in sales volumes to 26,117 Boe/d. Despite the revenue growth, the company recorded a net loss of $34.0 million while generating $65.3 million in Adjusted EBITDA.
Term
Q3 2026
“Prairie’s third-quarter results demonstrate the strength of our assets and the excellent work our team continues to deliver across our development program. Average daily sales volumes increased 21% from the prior quarter to 2.4 MMboe or 26,117 Boe per day, driving revenue growth of 31% from the prior quarter to $129.5 million. We achieved that growth while reducing lease operating expense per Boe by 17% from the prior quarter, reflecting our continued focus on improving well performance and operating efficiency.”
Greg Patton, Chief Executive Officer
“Prairie generated $65.3 million of Adjusted EBITDA in the third quarter, an increase of 92% from the prior quarter, as sales volumes increased and unit operating costs declined. With Burnett and Castor now producing, our focus is on realizing the cash returns from the capital invested this year and carefully managing the spending required to sustain that production.”
Michael Shelly, Executive Vice President and Chief Financial Officer
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company with two product candidates, BH-30643 and BH-30236, in early clinical development and one preclinical candidate, BH-501284. The company has incurred substantial losses since inception and anticipates continued losses as it advances its precision medicine programs for genetically defined cancers.
Addus HomeCare EVP, Chief Development Officer Cliff Donald Blessing Sells $429K of Stock
Cliff Donald Blessing, EVP, Chief Development Officer, sold 3,464 shares of Addus HomeCare Corp at $123.10 to $124.18 a share (average $123.90) in 2 transactions, worth $429K in total on Nov 10, 2026. Shares held after the trade: 6,719 (-27.7%).
General American Investors Co VP Administration Eugene S. Stark Buys $21.9K of Stock
Eugene S. Stark, VP Administration, bought 1,000 shares of General American Investors Co Inc at $21.95 a share, worth $21.9K in total on Nov 12, 2026. Shares held after the trade: 40,000 (+2.6%).
Legacy Education Inc. reported financial results for its fiscal first quarter ended September 30, 2026, featuring record student population growth of 5.4% year-over-year to 3,684 students. The company achieved revenue of $20.0 million and net income of $0.9 million while expanding its footprint with a new lease for its first planned campus outside California in Houston, Texas.
Sempreon 10% Owner Caroline Lux Kaplan Sells $1.08M of Stock
Caroline Lux Kaplan, 10% Owner, sold 60,000 shares of Sempreon, Inc at $17.63 to $18.26 a share (average $17.94) in 2 transactions, worth $1.08M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 410,958 (-6.8%).
National Bankshares, Inc. declared a semi-annual cash dividend of $0.78 per share. The dividend is payable on December 1, 2026, to stockholders of record as of the close of business on November 23, 2026.
Legence Corp. reported significant growth in total assets to $3.83 billion as of September 30, 2026, up from $2.68 billion at year-end 2025, driven by increases in contract assets and intangible assets. The company maintained a dual-class share structure with 108,527,517 total shares outstanding and reported a reduction in its accumulated deficit from $309.9 million to $232.1 million during the period.
Stevanato Group S.p.A Director William J. Federici Buys $274K of Stock
William J. Federici, Director, bought 20,000 shares of Stevanato Group S.p.A. at $13.72 a share, worth $274K in total on Nov 9, 2026. Shares held after the trade: 46,991 (+74.1%).
Goldentree Asset Management LP bought 150,652 shares of Keenova Therapeutics plc at $89.25 to $91.00 a share (average $90.65) in 2 transactions, worth $13.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 9,026,195 (+1.4%).
Consensus Cloud Solutions Director Nathaniel Simmons Sells $342K of Stock
Nathaniel Simmons, Director, sold 8,000 shares of Consensus Cloud Solutions, Inc. at $42.46 to $42.90 a share (average $42.78) in 2 transactions, worth $342K in total on Nov 9, 2026. Shares held after the trade: 23,658 (-19.6%).
LEE ENTERPRISES Director David Henry Hoffmann Buys $99.3K of Stock
David Henry Hoffmann, Director, bought 14,056 shares of LEE ENTERPRISES, Inc at $6.96 to $7.17 a share (average $7.07) in 2 transactions, worth $99.3K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 11,544,637 (+0.1%).
Claritev Insider Ares Management LLC Buys $2.94M of Stock
Ares Management LLC bought 115,579 shares of Claritev Corp at $24.42 to $26.14 a share (average $25.40) in 2 transactions, worth $2.94M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,049,518 (+3.3%).
Intercontinental Exchange General Counsel Andrew J. Surdykowski Sells $801K of Stock
Andrew J. Surdykowski, General Counsel, sold 4,575 shares of Intercontinental Exchange, Inc. at $174.04 to $176.22 a share (average $175.05) in 3 transactions, worth $801K in total on Nov 10, 2026. Shares held after the trade: 40,554 (-1.4%).
CareDx Secretary and General Counsel Jeffrey Adam Novack Sells $332K of Stock
Jeffrey Adam Novack, Secretary and General Counsel, sold 4,096 shares of CareDx, Inc. at $80.47 to $83.33 a share (average $81.13) in 3 transactions, worth $332K in total on Nov 10, 2026. Shares held after the trade: 96,604 (-0.9%).
Audax Private Credit Fund, LLC reported a net increase in net assets from operations of $25.6 million for the nine months ended September 30, 2026, compared to $15.2 million in the prior year period. Total investments at fair value grew to $1.21 billion, while the fund maintained a net asset value per share of $24.86.
KBS Real Estate Investment Trust III, Inc. reported a net loss of $137.1 million for the nine months ended September 30, 2026, compared to a $59.9 million loss in the prior year period. The increased loss was driven by $80.0 million in real estate impairment charges and a $19.2 million unrealized loss on real estate equity securities.
Solaris Energy Infrastructure Insider Aj Teague Buys $30.8K of Stock
Aj Teague bought 520 shares of Solaris Energy Infrastructure, Inc. at $59.23 to $59.50 a share (average $59.32) in 2 transactions, worth $30.8K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 117,385 (+0.1%).
Toast Insider Susan Chapman-Hughes Sells $235K of Stock
Susan Chapman-Hughes sold 6,885 shares of Toast, Inc. at $34.13 a share, worth $235K in total on Nov 11, 2026. Shares held after the trade: 7,645 (-47.4%).
Planet 13 Holdings reported Q3 2026 revenue of $23.1 million, a 1.0% sequential increase driven by strong growth in Florida. The company significantly reduced its net loss to $6.4 million compared to $44.0 million in the prior year, aided by improved gross margins and the exit from California operations. Management highlighted the upcoming December 10 shareholder vote on its proposed merger with Vireo Growth.
Term
Q3 2026
“Revenue increased for the second consecutive quarter, up 1.0% sequentially, led by a 15.1% quarter-over-quarter increase in Florida, where revenue was 45% higher than in the prior-year quarter. The levers we have been pulling in Florida are showing up in the numbers driven by better flower out of our upgraded cultivation, a fuller product lineup with BHO concentrates now on shelf, and a more productive store network.”
Larry Scheffler, Co-CEO of Planet 13
“We delivered a second consecutive quarter of revenue growth and Adjusted EBITDA improvement, and our focus remains on running the business well and executing a smooth path to closing for our stockholders, employees, patients and customers. With the Form S-4 declared effective on November 2, our stockholders will vote on the proposed merger with Vireo Growth at a special meeting on December 10, 2026.”
Verrica Pharmaceuticals reported record Q3 2026 YCANTH net product revenue of $5.7 million, a 57.9% increase year-over-year, and total revenue of $6.9 million. The company completed enrollment in its first Phase 3 pivotal trial for common warts and unlocked $27.5 million in non-dilutive growth capital by meeting credit facility milestones.
Term
Q3 2026
“Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer
“Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer